N-(5-氯-6-(喹啉-3-氧基)吡啶-3-基)-3,4-二氟苯磺酰胺 | 1013696-08-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: N-(5-氯-6-(喹啉-3-氧基)吡啶-3-基)-3,4-二氟苯磺酰胺
• 英文名称: N-(5-chloro-6-(quinolin-3-yloxy)pyridin-3-yl)-3,4-difluorobenzenesulfonamide
• 英文别名: N-(5-chloro-6-quinolin-3-yloxypyridin-3-yl)-3,4-difluorobenzenesulfonamide
• CAS: 1013696-08-6
• 化学式: C₂₀H₁₂ClF₂N₃O₃S
• 分子量: 447.849
• InChiKey: XAXFAGJYAZYRDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  89.6
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-羟基-5-硝基吡啶 在 吡啶 、 喹啉 、 盐酸 、 tin(II) chloride dihdyrate 、 caesium carbonate 、 三氯氧磷 作用下， 以 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 11.5h， 生成 N-(5-氯-6-(喹啉-3-氧基)吡啶-3-基)-3,4-二氟苯磺酰胺
  参考文献：
  名称：

  Synthesis of N-(5-chloro-6-(quinolin-3-yloxy)pyridin-3-yl)benzenesulfonamide derivatives as non-TZD peroxisome proliferator-activated receptor γ (PPARγ) agonist

  摘要：

  The thiazolidinediones (TZDs) are a class of oral antidiabetic drugs that improve insulin sensitivity in patients with type 2 diabetes. Although the mechanism by which the TZDs lower insulin resistance is unclear, they are known to target the peroxisome proliferator-activated receptor gamma (PPAR gamma), a nuclear hormone receptor. Ligands for PPAR gamma regulate adipocyte production and secretion of fatty acids as well as glucose metabolism, resulting in increased insulin sensitivity in adipose tissue, liver, and skeletal muscle. However, TZDs have several adverse effects, including weight gain and liver toxicity. Herein we report identification of non-TZD PPAR gamma agonists which exhibit beneficial effects similar to that of TZDs in animal models, but without the associated adverse effects. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.10.027

文献信息

• 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS
  申请人：Deka Nabajyoti

  公开号：US20090247574A1

  公开（公告）日：2009-10-01

  The present invention provides novel compounds represented by the general formula (I): their pharmaceutically acceptable salts and their pharmaceutically acceptable solvates thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia. The invention also relates to a process for the manufacture of compounds of formula (I) and pharmaceutical compositions containing them.

  本发明提供了一种由通式(I)所代表的新化合物：它们的药学上可接受的盐和药学上可接受的溶剂，用于治疗与胰岛素抵抗或高血糖有关的代谢紊乱。本发明还涉及制备通式(I)化合物和含有它们的制药组合物的过程。
• 3-amino-pyridine derivatives for the treatment of metabolic disorders
  申请人：Piramal Healthcare Limited

  公开号：US08269010B2

  公开（公告）日：2012-09-18

  The present invention provides novel compounds represented by the general formula (I): their pharmaceutically acceptable salts and their pharmaceutically acceptable solvates thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia. The invention also relates to a process for the manufacture of compounds of formula (I) and pharmaceutical compositions containing them.

  本发明提供了一种新的化合物，其通式表示为（I）：其药学上可接受的盐和药学上可接受的溶剂，可用于治疗与胰岛素抵抗或高血糖相关的代谢紊乱。本发明还涉及制备通式（I）化合物的方法和包含它们的药物组合物。
• 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS
  申请人：Piramal Life Sciences Limited

  公开号：EP2094687A1

  公开（公告）日：2009-09-02
• US8269010B2
  申请人：——

  公开号：US8269010B2

  公开（公告）日：2012-09-18
• [EN] 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE TROUBLES DU MÉTABOLISME
  申请人：NICHOLAS PIRAMAL INDIA LTD

  公开号：WO2008035306A1

  公开（公告）日：2008-03-27

  [EN] The picsenl invention provides novel compounds represented by the general formula (I): wherein Ar is a quinoline or isoquinoline moiety which is substituted or unsubstituted; B is -O. -S-. or -NH-: R¹ is hydrogen or S(O)₂R⁴: R² is S(O)₂R⁴. C(O)OR⁵. or C(O)(CH₂)_n-C(O)OR⁶: R³ is halogen, cyano, C(O)OR⁷. or C(O)NR⁸R⁹: R⁴ is aryl: R⁵ is (C₁-C₆)alkyl or aryl: R⁶ is hydrogen. (C₁-C₄)alkyl. or aryl: R⁷ is hydrogen or (C₁-C₄)alkyl: R⁸ and R⁹ are independently hydrogen or (C₁-C₆)alkyl; n is an integer from 1-3: and a pharmaceutically acceptable salt or solvate thereof. their pharmaceutically acceptable salts and their pharmaceutically acceptable solvates thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia. The invention also relates to a process for the manufacture of compounds of formula (I) and pharmaceutical compositions containing them.
  [FR] La présente invention concerne des composés représentés par la formule générale (I) et certains de leurs sels et solvates pharmaceutiquement admis, convenant pour le traitement de troubles du métabolisme en lien avec la résistance à l'insuline ou l'hyperglycémie. L'invention concerne également un procédé de fabrication des composés représentés par la formule (I) et des compositions pharmaceutiques les contenant.